Business
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck's Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
Opioid-Pusher Pidduck, Chairman Chris Taves and the Current MediPharm Board Have Presided Over $1...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma\n\n\n\n\n\n Opioid-Pusher Pidduck, Chairman Chris Taves and the Current MediPharm Board Have Presided Over $1 Billion in Shareholder Value Destruction while funneling $5,587,059 of the Shareholders’ Money Directly into Pidduck’s Pocket\n \n\n\n\n\n\n Apollo Capital’s Six Director Nominees Are Committed to Restoring Transparency and Value to MediPharm’s Shareholders\n \n\n\n\n\n\n URGES SHAREHOLDERS TO DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD AND VOTE THE\n \n\n\n\n\n GOLD\n \n\n\n\n\n PROXY CARD \"FOR\" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES\n \n\n\n\n TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs”, or the “Company”), owning approximately 3% of the Company’s common stock, today issued a statement regarding CEO David Pidduck’s background as former CEO & President of Purdue Pharma Canada (“Purdue Pharma”).\n \n\n Fellow shareholders deserve to know the truth regarding CEO David Pidduck. As stewards of a publicly traded company, MediPharm’s Board of Directors (the “Board”) have a responsibility to uphold transparency, accountability, and good governance. The current Board, which has overseen $1 billion of shareholder value destruction, and which has presided over an eye-watering 99% share price decline, is focused on downplaying Mr. Pidduck’s past, rather than its responsibilities to shareholders. Indeed, there was absolutely\n \n no\n \n reference to Pidduck’s role at Purdue Pharma, or of Purdue Pharma’s culpability in creating the opioid epidemic, in the Company’s\n \n press release\n \n announcing Mr. Pidduck’s appointment as CEO.\n \n\n Let’s look at the facts:\n \n\n From 2014 until December 2021, David Pidduck served as VP of Marketing, and then...